Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Cancers (Basel)
; 15(6)2023 Mar 13.
Article
in En
| MEDLINE
| ID: mdl-36980628
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
Cancers (Basel)
Year:
2023
Document type:
Article
Affiliation country:
France
Country of publication:
Switzerland